Lumos Diagnostics Holdings Ltd (AU:LDX) — Market Cap & Net Worth
Market Cap & Net Worth: Lumos Diagnostics Holdings Ltd (LDX)
Lumos Diagnostics Holdings Ltd (AU:LDX) has a market capitalization of $71.91 Million (AU$101.63 Million) as of September 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20573 globally and #692 in its home market, demonstrating a 10.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lumos Diagnostics Holdings Ltd's stock price AU$0.11 by its total outstanding shares 923874135 (923.87 Million). Also see LDX asset base for a full breakdown of the balance sheet.
Lumos Diagnostics Holdings Ltd Market Cap History: 2021 to 2026
Lumos Diagnostics Holdings Ltd's market capitalization history from 2021 to 2026. Data shows change from $603.76 Million to $71.91 Million (-37.00% CAGR). Also see Lumos Diagnostics Holdings Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Lumos Diagnostics Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lumos Diagnostics Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Lumos Diagnostics Holdings Ltd (LDX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.83x
Lumos Diagnostics Holdings Ltd's market cap is 1.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $603.76 Million | $11.63 Million | -$45.72 Million | 51.91x | N/A |
| 2022 | $31.38 Million | $10.54 Million | -$8.97 Million | 2.98x | N/A |
| 2023 | $47.72 Million | $11.13 Million | -$8.59 Million | 4.29x | N/A |
| 2024 | $22.88 Million | $12.50 Million | -$7.18 Million | 1.83x | N/A |
Competitor Companies of LDX by Market Capitalization
Companies near Lumos Diagnostics Holdings Ltd in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Lumos Diagnostics Holdings Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lumos Diagnostics Holdings Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Lumos Diagnostics Holdings Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Lumos Diagnostics Holdings Ltd's market cap moved from $603.76 Million to $ 71.91 Million, with a yearly change of -37.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$71.91 Million | -61.40% |
| 2025 | AU$186.30 Million | +714.29% |
| 2024 | AU$22.88 Million | -52.05% |
| 2023 | AU$47.72 Million | +52.08% |
| 2022 | AU$31.38 Million | -94.80% |
| 2021 | AU$603.76 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Lumos Diagnostics Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.91 Million USD |
| MoneyControl | $71.91 Million USD |
| MarketWatch | $71.91 Million USD |
| marketcap.company | $71.91 Million USD |
| Reuters | $71.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more